Brief: Paion reports positive headline data in US clinical safety trial of Remimazolam

PAION AG

27/03/2017 06:30

March 27 (Reuters) - Paion AG  PA8G.DE : 
    * Reports positive headline data in U.S. clinical safety 
trial of Remimazolam in high-risk patients undergoing 
colonoscopy 
    * Remimazolam administration appeared safe 
    * Efficacy and efficiency gains comparable to confirmatory 
U.S. phase III pivotal trial 
    * Overall, Remimazolam demonstrated good respiratory and 
cardiovascular stability as compared to placebo with Midazolam 
rescue 
    * No adverse events of concern were observed in either group 
 
Source text for Eikon:  ID:nEQ2tQnQ3  
Further company coverage:  PA8G.DE  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))